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The emergence of drug-resistant bacteria coupled
with the limited discovery of novel chemical scaffolds
and druggable targets inspires new approaches to
antibiotic development. Here we describe a chemical
genomics strategy based on 245 Staphylococcus
aureus antisense RNA strains, each engineered for
reduced expression of target genes essential for
S. aureus growth. Attenuation of gene expression
can sensitize cells to compounds that inhibit the
activity of a gene product or associated process.
Pools of strains grown competitively in the presence
of bioactive compounds generate characteristic
profiles of strain sensitivities reflecting compound
mechanism of action. Here, we validate this ap-
proach with a structurally and mechanistically
diverse set of reference antibiotics and, in the ac-
companying paper in this issue of Chemistry &
Biology (Huber et al., 2009), demonstrate its use in
the discovery of new cell wall inhibitors.
INTRODUCTION
The need to develop novel antibiotics to combat emerging or
established resistance to existing antibacterial therapies is
universally acknowledged (Taubes, 2008). Unfortunately, the
search for new antibacterial drugs remains a significant chal-
lenge (Payne et al., 2007), with only two novel therapeutics (line-
zolid and daptomycin) resulting from efforts spanning the last 20
years. One of the major limitations in the screening of compound
libraries for antibacterials is the large number of hits coming from
compounds working through a nonspecific mechanism of action
(MOA). Until recently, methods that can identify antibiotics that
selectively inhibit well validated or high value targets have
been lacking.
Fortunately, an elegant chemical genomics strategy that
allows for a quick readout of a compound’s potential MOA in
a living cell has emerged from the yeast research community.
The approach, termed haploinsufficiency profiling (also referred826 Chemistry & Biology 16, 826–836, August 28, 2009 ª2009 Elsevto as the yeast fitness test), relies on the observation that reduc-
tion in the copy number of genes encoding particular protein
targets sensitizes the cell to selective inhibitors, reducing its
fitness relative to other heterozygote strains whose copy number
mutations are unrelated to compound MOA (Baetz et al., 2004;
Giaever et al., 1999, 2004; Lum et al., 2004). Haploinsufficiency
resulting from compound treatment is quantified by microarray
hybridization of amplified barcode tags, allowing inferences to
be made regarding MOA. An analogous fitness test platform
for the fungal pathogen Candida albicans (CaFT) has recently
been developed and validated with a variety of well character-
ized antifungal compounds (Rodriguez-Suarez et al., 2007; Xu
et al., 2007). The CaFT platform has been further utilized in
a natural products discovery paradigm to discover a novel inhib-
itor of fungal poly(A) polymerase with drug-like properties that
include efficacy in an animal model of disseminated candidiasis,
demonstrating the practical utility of the fitness test strategy for
antimicrobial drug discovery (Jiang et al., 2008).
The use of hypersensitized strains as chemical genetic tools in
bacteria is feasible with regulated systems that repress essential
gene expression either through the construction of conditional
gene knockouts (DeVito et al., 2002) or by inducible antisense
RNA (Forsyth et al., 2002; Ji et al., 2001). Such strains have
been used, individually or in parallel, for the screening of syn-
thetic or natural product compound libraries (DeVito et al.,
2002; Young et al., 2006). The concept of using a pool of sensi-
tized antisense strains in bacteria to identify compoundMOAhas
previously been explored (Yin et al., 2004), but the full potential of
this approach as a chemical genomics platform has not yet been
realized. Herein we describe the first use of an integrated array of
hypersensitized strains to systematically profile the MOA of
small molecule antibiotics in a clinically significant pathogenic
bacterium. Represented in this S. aureus array are 245 strains
that correspond to essential genes for which xylose-inducible
antisense RNA expression imparts a growth phenotype. This
semiautomated system is capable of generating antisense-
induced strain sensitivity (AISS) profiles reflecting the mecha-
nistic selectivity of a structurally diverse set of reference antibi-
otics for a variety of known targets including the cell wall, the
ribosome, nucleic acid biosynthesis, and several metabolic
pathways. The platform has broad applications in the field of
antibacterial drug discovery, including MOA determination forier Ltd All rights reserved
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Staphylococcus aureus Fitness Testnewly discovered antibacterial agents, the identification of novel
drug targets, and the detection of reporter strains whose chem-
ically-induced hypersensitivity correlates with specific antibac-
terial modes of action.
RESULTS
Experimental Design
The majority of the 245 S. aureus antisense strains of the array
(see Table S1 available online) were selected from a broader
collection of 658 strains with conditional growth phenotype
generated using a genome-wide shotgun cloning strategy (For-
syth et al., 2002). The array includes 30 additional strains con-
structed by targeted cloning to improve representation of genes
Figure 1. Binning of Antisense Strains
(A) Dose response curves for a subset of antisense
strains and empty vector control strain illustrate
variable sensitivity to xylose inducer.
(B) Distribution of strains into 24 bins (color
coded). Data from multiple experiments were
averaged (n > 3) and IC10 and IC30 values were
interpolated from nonlinear regression analysis
(Experimental Procedures). y axis represents the
rank ordering of sensitivities from most sensitive
(top) to least sensitive (bottom), based on IC20
values. Left and right boundaries of horizontal
bars represent the xylose IC10 and IC30 values
while bar length reflects the relative slope. Inset
highlights bins 15 and 16.
known to be essential in other bacterial
pathogens or that constitute validated
gene targets. Represented in the array
are genes involved in cell wall biosyn-
thesis, ribosomal protein synthesis, fatty
acid biosynthesis, DNA synthesis and
replication, and RNA transcription. Also
present are antisense strains corre-
sponding to genes encoding glycolytic
enzymes, tRNAs, tRNA-modifying en-
zymes, tRNA synthetases, chaperones,
cell division proteins, enzymes of vitamin
cofactor metabolism and oxidative phos-
phorylation, as well as some proteins of
uncertain function. The antisense gene
fragments map to 140 different operons
containing between 1 and 29 open
reading frames (Table S2).
In fungal systems for fitness test pro-
filing all of the heterozygote strains can
be pooled together (Giaever et al., 2004;
Giaever et al., 1999; Lum et al., 2004; Xu
et al., 2007) and the magnitude of the
target gene depletion is fixed (at 50%).
AISS profiling in S. aureus has the com-
plexity of titratable levels of antisense
expression and corresponding target
protein depletions with strains displaying
variable sensitivity to the xylose inducer
(Figure 1A), which precludes combining all of the antisense
strains into one pool. To achieve comparable levels of sensitivity
and competitive growth, the 245 antisense strains were divided
into 24 pools of 6–12 strains each that respond similarly to xylose
inducer (Figure 1B). Xylose levels of individual bins varied
between 1.8 and 55mM (final concentration). To maximize strain
sensitivity, we chose to perform the experiment at xylose levels
that induce a modest growth defect in the antisense strains (tar-
geted range of IC10–IC30), thereby establishing some biologically
significant level of target protein depletion.
An overview of the AISS profiling platform that illustrates
sequential microbiology, molecular biology, and data analysis
steps is shown in Figure 2. The 24 bins were grown in parallel
in the presence of a range of partially inhibitory concentrationsChemistry & Biology 16, 826–836, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 827
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The 245 strains comprising the array are pooled
into 24 distinct bins, with each bin assayed at
a different final xylose concentration from 1.8 to
55 mM. The bins are grown for 20 generations
in the presence of test compound or 2% DMSO
(mock treatment). After pooling, cells are lysed
and transferred into multiplex PCR reactions
for amplification with eight distinct sets of
strain-specific oligonucleotide primers (termed
marker sets). Approximately 30 different antisense
markers are amplified per reaction, with each rep-
resenting a unique antisense strain in the array.
PCR products from each of the eight reactions
are separated by capillary electrophoresis and
identified and peak areas quantified. Captured
data is then systematically quality controlled and
normalized. Depletion ratios and statistical signifi-
cance values are generated by comparing
markers from the test compound treatment to
those of the DMSO control (Experimental Proce-
dures). AISS profiles resulting from the analysis
are also subjected to higher level 2D cluster anal-
ysis (Rosetta Resolver).of antibiotic for approximately 20 population doublings. At the
end of the growth period, the relative abundances of each of
the strains in the compound treatment and DMSO mock treat-
ment groups were determined by multiplex PCR, capillary elec-
trophoresis, and DNA fragment analysis to quantify strain-
specific markers. Depletion ratios and statistical significance
were generated from normalized peak area data by comparing
test PCR marker abundances with mock DMSO controls (See
Experimental procedures), yielding AISS profiles for each
compound. Representative growth data (Figure 3A), PCR frag-
ment analysis (Figure 3B), and the corresponding AISS profile
(Figure 3C) are shown for platensimycin. In order to highlight
only those strains depleting across the full range of compound
concentrations presented, data were stringently filtered to
show only strain depletions represented in greater than 90% of
the doses. Selective depletion of the fabF-antisense (AS) strain
in response to compound treatment is in accordance with pla-
tensimycin’s well established MOA through inhibition of the
FabF enzyme (Wang et al., 2006). Additional less consistently
represented depletions in accA/C-AS (acetyl-CoA carboxylase)
strains are shown in Table S3 and the unfiltered average
response for the 245 strains in the array is depicted in
Figure S1. To validate our approach for determining the MOAs
of antibacterial compounds, we systematically profiled 59
antibacterial compounds (Table S4). Log depletion ratios and
p-values were calculated for all strains for each of the qualified
compound treatments (Tables S5 and S6).
Inhibitors of Enzyme Targets
Additional examples of AISS profiles of selective enzyme inhibi-
tors are shown in Figure 4. Trimethoprim is a synthetic antifolate
that inhibits dihydrofolate reductase (Burchall, 1973; Hitchings,
1973), an enzyme which regenerates reduced tetrahydrofolate
for the biosynthesis of thymidylate, purines, histidine, andmethi-
onine. The associated AISS profile (Figure 4A) shows strong828 Chemistry & Biology 16, 826–836, August 28, 2009 ª2009 Elsevdepletions for antisense strains corresponding to the enzymatic
target dihydrofolate reductase (dfrA-AS) and for the enzymati-
cally coupled thymidylate synthase (thyA-AS). Depletions are
also observed for antisense strains associated with DNA replica-
tion: dnlJ-AS (DNA ligase); recR-AS (recombination protein); and
dnaX-AS (polIII g subunit). Thus, in addition to AISS profiling
identifying the established target of trimethoprim, its down-
stream effects on DNA replication are also revealed.
Novobiocin inhibits the catalytic activity of the related hetero-
tetrameric topoisomerase enzymes, DNA gyrase and topoismer-
ase IV (Bellon et al., 2004; Fujimoto-Nakamura et al., 2005). Its
AISS profile (Figure 4B) shows highly significant depletions in
both topoisomerase IV strains parE-AS and parC-AS as well as
significant depletions for the two DNA gyrase strains gyrB-AS
and gyrA-AS. Thus, each of the known multimeric enzyme
complexes targeted by novobiocin is faithfully resolved. Addi-
tional, less consistently represented strain depletions reflected
in the novobiocin AISS profile (Table S3 and Figure S2) corre-
spond to genes that presumably buffer the cell from the DNA
damaging effects of novobiocin; these include the DNA poly-
merase III delta prime and a subunits (holB-AS and polC-AS,
respectively) and hu-AS. The Hu protein is a dimeric histone-
like DNA binding protein associated with DNA recombination
and DNA repair (Kamashev et al., 2008).
D-cycloserine is a cell wall biosynthesis inhibitor that inhibits
alanine racemase (Alr) and D-alanine-D-alanine ligase (DdlA)
(Feng and Barletta, 2003; Lambert and Neuhaus, 1972). Both
alr and ddlA-AS strains are strongly depleted in the D-cyclo-
serine AISS profile (Figure 4C). Depletions of similar magnitude
but lower significance are also seen for the murF-AS strain.
The murF gene is cotranscribed with ddlA and catalyzes
the addition of the carboxy terminal D-ala-D-ala dipeptide
substrate provided by the cooperative functions of Alr and
DdlA to sequentially assemble the peptidoglycan precursor.
Therefore, AISS profiling of D-cycloserine identifies its cognateier Ltd All rights reserved
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(A) Growth data from a platensimycin experiment. The x axis represents time (in hours) and the y axis the growth (OD600) for the 24 bins corresponding to each
treatment (mean with SD for six doses and DMSO control from two independent experiments). To attain 20 population doublings the cells are grown for three
cycles with appropriate back dilutions and seeding into fresh media and drug at every cycle. Readings are taken at the end of each period (at approximately 8, 13,
and 18 hr) and percentage of growth inhibition relative to the control is calculated for each compound dose at the end of the third cycle (legend). Data from the
DMSO control and 0.041 mg/ml dose are highlighted in blue and red, respectively. The 0.15 mg/ml dose (62% growth inhibition; dotted line) is automatically
invalidated according to QC criteria (>60% threshold).
(B) Capillary electrophoresis profile of a subset of strain-specific fragments (400–500 nt range) frommarker set 8 that includes fabF-AS. Thismarker is detected by
multiplex PCR in the cell lysate frommock-treated cells (highlighted in green) but not from cells treated with platensimycin (asterisk). Grey bars represent marker-
specific mobility ranges recognized by the ABI Genemapper software.
(C) The completed AISS profile of platensimycin, generated from normalized data (see Experimental Procedures), includes doses from a total of five experiments.
The log2 depletion ratio is shown on the y axis and represents the fold strain depletion versus DMSOmock controls. The z score denoting the significance of the
depletion shown on the x axis is derived from strain-specific error models. Data points represent individual compound doses.drug target along with an interdependent step in peptidoglycan
synthesis indirectly affected by the compound’s mode of
action.
Unlike the above clinically used antibiotics, compound D
constitutes a new predevelopment small molecule whose in-
hibitory effect has been linked to the largely uncharacterized
gene SAV1754 (Mott et al., 2008), annotated as SA1575 in the
S. aureus N315 genome. Consistent with its predicted drug
target, AISS profiling of compound D highlights dramatic andChemistry & Biology 16, 8highly significant depletions of the SAV1754-AS strain (Fig-
ure 4D), corroborating its reported MOA. Based on highly related
AISS profiles between compound D and two newly discovered
bioactive compounds (DMPI and CDFI) described in an accom-
panying paper by Roemer and colleagues (Huber et al., 2009
[this issue of Chemistry & Biology]), we demonstrate by genetic
means that this latter class also likely targets SAV1754 and
propose that SAV1754 may function as a peptidoglycan pre-
cursor flippase.26–836, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 829
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Inhibition at Enzyme Targets
(A) trimethoprim and dfrA/thyA; (B) novobiocin
and gyrA/B, parC/E (gyrase/topoisomerase); (C)
D-cycloserine and alr/ddlA; (D) compound D and
SAV1754. Data points represent independent
compound doses across a minimum of two pro-
filing experiments. Data were stringently filtered
to show only strain depletions represented in
>90% of the doses, with log2 ratio and z score
thresholds set at 1.8 and 2.0, respectively. Addi-
tional less consistent compound-induced strain
depletions are represented in Table S3 and the
unfiltered average responses for the 245 strains
to each of these compounds are represented in
Figure S2.Two-Dimensional Cluster Analysis of the Reference
Data Set
A 2D hierarchical clustering of AISS profiles from all of the
compounds and significantly depleted strains demonstrates
the overall relationship between AISS profiles of compounds
with either similar or diverse biological MOAs (Figure 5). The
compound profiles group into four major branches (A–D), which
broadly represent different modes of antibacterial action.
AISS profiles of DNA intercalators, DNA damaging agents, and
inhibitors of DNA gyrase and topoisomase form the first branch
of the cluster (Figure 5, group A). This branch is comprised of
four major subgroups: profiles of the DNA binding drugs actino-
mycin D, echinomycin, and daunorubicin; the four fluoroquino-
lone DNA gyrase and topoisomerase IV inhibitors (ciprofloxacin,
norfloxacin, nadifloxacin, and gatifloxacin); the nonenzyme-
mediated DNA damaging agent streptonigrin; and the coumarin
DNA gyrase and topoisomerase IV inhibitors novobiocin and
coumermycin.
Actinomycin and echinomycin are structurally similar com-
pounds that block RNA synthesis by binding to the minor groove
of double stranded DNA (Sobell, 1985; Waring and Wakelin,
1974). Actinomycin can also interfere with DNA replication and
has been used as an antitumor agent. Their complex but
tightly clustering profiles (0.82 correlation) are characterized by
common depletions in antisense strains corresponding to genes
on a 29-member superoperon. These antisense strains include
adk (adenosine kinase), secY (protein secretion), rpsK, rplQ,
rpsM, rpsE, rplN, rplP (ribosomal proteins), infA (initiation factor),
and rpoA (RNA polymerase a subunit). A possible explanation for
this characteristic signature is that hypersensitivity of these
strains to the DNA intercalators is a secondary consequence of
antisense interference with expression of the cotranscribed
rpoA gene (see Discussion).
Daunorubicin is an anthracycline antitumor agent that binds
DNA and induces covalent interstrand DNA crosslinks leading
to double strand breaks (Fukushima et al., 1993; Sartiano
et al., 1979; Skladanowski and Konopa, 1994). Its profile shows
some overlap with actinomycin and echinomycin, but strong
uncommon depletions in recR-AS and gyrB-AS strains are also830 Chemistry & Biology 16, 826–836, August 28, 2009 ª2009 Elsevpresent. Depletions in the recR and hu-AS strains are shared
by the nonselective DNA damaging agent streptonigrin and the
fluoroquinolones, which induce double-stranded breaks through
selective inhibition of topoisomerase. The S. aureus RecR pro-
tein is the orthologue (39% identity) of the E. coli RecR enzyme
that is involved in recombinational DNA repair (Chow and Cour-
celle, 2004; Ivancic-Bace et al., 2003; Morimatsu and Kowalczy-
kowski, 2003).
In contrast to the profiles of the four fluoroquinolone topoiso-
merase inhibitors, the AISS profiles of novobiocin and coumer-
mycin show strong depletions in the parC-AS and parE-AS
(topoisomerase IV subunits) strains, reflecting differences in
the MOAs of these two distinct classes of topoisomerase inhib-
itors that are supported by a large body of molecular and
biochemical evidence (reviewed in Drlica, 1999; Oblak et al.,
2007). Interestingly, the representation of these strains in the
AISS assay is enhanced (rather than depleted) by fluoroquino-
lone treatment (Figure 5, cyan-colored parC and parE tiles). By
effectively reducing the level of topoisomerase, antisense ex-
pression appears to confer a fitness advantage to drug-treated
cells by mitigating the associated enzyme-mediated toxicity.
Also clustering within group A is trimethoprim (see also
Figure 4A) and the RNA polymerase inhibitor rifampin. The
antisense strains most consistently depleted by rifampin are
sigA-AS (RNA polymerase sigma factor) and rpoC-AS (RNA
polymerase b0 subunit), although a variety of DNA replication-
associated strains are also depleted. Rifampin inhibits transcrip-
tion by binding to the b subunit of the RNA polymerase core
enzyme complex (reviewed in Wehrli, 1977). Structural evidence
also suggests that b subunit binding by rifampin induces an allo-
steric change that can affect the sigma factor interaction (Artsi-
movitch et al., 2005).
A broad range of antibiotics compromise the peptidoglycan
cell wall and underlying plasma membrane. Targets include
intracellular enzymes of isoprenoid and cell wall biosynthesis,
as well as transglycolases (TG) and transpeptidases (TP) located
external to the plasma membrane. AISS profiles from 18
compounds that interfere diversely with the integrity of the cell
wall and plasma membrane form the second major branch ofier Ltd All rights reserved
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Staphylococcus aureus Fitness TestFigure 5. Two-Dimensional Cluster Analysis of AISS Profiles for 59 Antibacterial Compounds and 101 Significantly Depleted Strains
Strain depletions are depicted in magenta and strain resistances in cyan (log10 ratio scale). Depletion ratio and p-value data for each compound are represented
as a combined profile (combo) of the set of profiles for a range of doses. The plot was generated using the Rosetta Resolver 2D cluster tool. Cluster parameters,
selection of significantly depleted strains for the analysis, and the generation of combos are described in the Experimental Procedures. The compound profiles
cluster into four major branches or subclusters: (A) a cluster of 12 nucleic acid synthesis/replication inhibitors; (B) a cluster of 16 cell wall biosynthesis inhibitors
along with isoprenoid biosynthesis inhibitor AB1233A and membrane depolarizer daptomycin; (C) a cluster of 5 aminoglycosides along with FAS inhibitors
platensimycin and platensin, and polymyxin B; and (D) a cluster of 20 protein synthesis inhibitors along with U-62162, a natural product inhibitor with an unknown
MOA. Highlighted antisense strains (red) are discussed in the text.the reference cluster (Figure 5, group B). Strong depletions in the
pbp2-AS strain define a major subgroup of this branch that
includes the profiles of TG and TP inhibitors affecting peptido-
glycan assembly and crosslinking, respectively. PBP2 is an
essential bifunctional enzyme of the penicillin binding protein
(PBP) family, possessing separate TG and TP domains
(Scheffers and Pinho, 2005). A highly correlated subgroupChemistry & Biology 16, 8(0.79 correlation) includes the cephalosporin cefotaxime and
the glycopeptide teicoplanin. Cefotaxime is a third generation
cephalosporin of the same structural class as ceftizoxime
(Greenwood et al., 1980), a highly selective inhibitor of the
S.aureusPBP2TP(LeskiandTomasz,2005).Teicoplanin isa lipo-
glycopeptide that binds to Lipid II and inhibits the transglycosyla-
tion step of peptidoglycan synthesis (reviewed in Kahne et al.,26–836, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 831
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planin profiles may reflect how both agents preferentially target
PBP2, albeit by mechanistically distinct means, with cefotaxime
preferentially acylating thePBP2TPactive site versus teicoplanin
binding to lipid II peptidoglycan precursor, which blocks
substrate recognition of the PBP2 TG activity (reviewed in
Ostash and Walker, 2005). Additional peptidoglycan substrate
inhibitors clustering in this group are cyclic depsipeptides
(enduracidin and ramoplanin) and glycopeptides (vancomycin
and ristocetin), which form distinct subgroups (each with 0.76
correlation). Whereas ramoplanin was originally thought to bind
Lipid I peptidoglycan substrate of MurG (Somner and Reynolds,
1990), ramoplanin and the structurally related natural product
enduracidin have been shown to preferentially bind Lipid II and
inhibit the TG step of peptidoglycan synthesis (Fang et al.,
2006). Consistent with this revised mechanism, both com-
pounds share a high degree of correlation between their AISS
profiles and other stage III TG and TP inhibitors. Interestingly,
two uncharacterized open reading frames corresponding to
SAV1892 and SAV1891 are revealed in the profiles of these
agents. The SAV1892 gene encodes a putative transglycosylase
(COG0769M, UDP-N-acetylmuramyl tripeptide synthetase-like),
while the cotranscribed SAV1891 gene encodes a poorly char-
acterized amidotransferase (COG3442). Based on their shared
hypersensitivity to these cell wall inhibitors, we speculate that
SAV1892 and/or SAV1891 may directly or indirectly function in
cell wall assembly. Moenomycin, a PBP2 TG inhibitor that
directly binds to bacterial TG enzymes (van Heijenoort, 2001;
Vogel et al., 2000), is rooted in this subgroup, largely due to the
selective hypersensitivity of pbp2-AS.
Depletions in the pbp2-AS strain are completely absent from
AISS profiles of b-lactams penicillin, amoxicillin, cloxacillin, imi-
penem, and cephalosporin C. Profiles for these compounds
(0.67 correlation) form the core of the second major subgroup
of the cell wall and plasmamembrane branch and include deple-
tions in additional PBP strains, pbpA-AS and/or pbp3-AS. This
subgroup is further characterized by depletions of a broader
range of cell wall-associated strains, including those corre-
sponding to glmS, murA, murB, murC, murE, murF, ftsZ, and
the previously described SAV1891/SAV1892. Similarly, the
AISS profile of compound D also clusters with cell wall inhibitors,
largely due to the common depletion of the SAV1754-AS strain
with this agent as well as with cephalosporin C and tunicamycin
treatments. However, unlike other cell wall inhibitors comprising
this group, compound D appears relatively selective for the
SAV1754-AS strain.
The third major branch (Figure 5, group C) of the cluster
comprises bactericidal aminoglycosides such as gentamicin as
well as lipid synthesis inhibitors (platensymicin and platensin)
and the membrane disrupter polymyxin B. Perhaps surprisingly,
these aminoglycosides form a group (root correlation value 0.74)
characterized by depletions that do not reflect inhibition of ribo-
somal protein synthesis. Prominent are depletions of strains
associated with fatty acid biosynthesis (hmrB, fabF, and accA/
B/C), ATP synthase (atpB/F), and protein translocation (yidC).
Although aminoglycosides bind to the ribosome and inhibit
protein synthesis, the cytocidal effects of aminoglycosides
cannot be explained by inhibition of protein synthesis alone
(reviewed in Hancock, 1981a, 1981b). Moreover, the lack of832 Chemistry & Biology 16, 826–836, August 28, 2009 ª2009 Elseva protein synthesis inhibition signature within their AISS profile
does not reflect technical limitations associated with antisense
interference of genes participating in ribosome and/or trans-
lation processes, as such elements are highly sensitive to other
classes of protein synthesis inhibitors, including the bacterio-
static aminoglycoside spectinomycin (see below). Instead,
AISS profiles are consistent with the hypothesis that the cytoci-
dality of these aminoglycosides involves (in part) compromising
the integrity of the plasma membrane by mistranslation of
membrane proteins, as recently reported (Kohanski et al., 2008).
The fourth major branch of the compendium cluster (Figure 5,
group D) contains 20 protein synthesis inhibitors and one anti-
bacterial of unknown MOA. The most hypersensitive and fre-
quently depleted antisense strain in this set of compounds is
rpsO-AS. The rpsO gene encodes ribosomal protein S15, which
is highly conserved among prokaryotes and is thought to play
a role in ribosome assembly (Culver et al., 1999; Held et al.,
1974). Immediately apparent from the hierarchical clustering is
the resolution of compounds into discrete subgroups, some
according to antibiotic structure and/or MOA. The first subgroup
characterized by rpsO-AS depletions contains four structurally
unrelated compounds (thiostrepton, hygromycinA, spectino-
mycin, and pactamaycin) with different mechanisms of ribo-
some binding (Bowen et al., 2005; Guerrero and Modolell,
1980; Wirmer and Westhof, 2006). The AISS profiles for these
compounds share additional depletions of tufA-AS, rplD-AS,
and rpoA-AS. The macrolides are divided into two distinct but
structurally related subgroups. Tylosin and spiramycin (0.90
correlation) contain a disaccharide at position 5 in the lactone
ring with a mycarose moiety that seems to be correlated with
inhibition of peptidyl transferase (Poulsen et al., 2000). Erythro-
mycin, azithromycin, and roxithromycin, which lack this moiety
and functional capability, form a separate subgroup (0.90 corre-
lation). Four tetracycline compounds cluster tightly together
(0.92 correlation) and show depletions of a variety of transla-
tion-associated strains, including rpsO-AS, rpmA-AS, rplC-AS,
tufA-AS (EF-Tu), and SAV1257-AS (EF-Ts).
Depletions of rpsO-AS are noticeably absent from the profiles
of GE2270A and puromycin. The profiles of these similarly clus-
tering compounds (0.64 correlation) share common depletions
of tufA-AS and SAV1257-AS (elongation factors Tu and Ts).
GE2270A binds to EF-Tu and inhibits its interaction with amino-
acylated tRNAs (Parmeggiani and Nissen, 2006; Selva et al.,
1991). Puromycin is an aminoacylated tRNA analogue that is
incorporated into the nascent polypeptide, but blocks elongation
due to the resulting nonhydrolysable amide bond (Azzam and
Algranat, 1973). Interestingly, the antibiotic U-62162, an epoxide
of the manumycin family with unknown MOA (Slechta et al.,
1982), clusters with GE2270A. In addition to depletions in the
elongation factor antisense strains, tRNA-associated strains
trmD-AS, glyS-AS, and tRNAGlu/Asp/Ser-AS are also hypersen-
sitive to both compounds.
DISCUSSION
Here we describe the successful adaptation of the fitness test
approach for compound MOA determination in the clinically
important bacterial pathogen S. aureus. Although the basic
concept of a collection of target-depleted, sensitized strainsier Ltd All rights reserved
Chemistry & Biology
Staphylococcus aureus Fitness Testgrown in a competitive fitness test is analogous to yeast-based
systems, the underlying technologies are different. The fungal
platforms rely on comprehensive genome-wide sets of heterozy-
gote strains and a DNA chip-based detection system. The anal-
ogous S. aureus platform utilizes a smaller collection of 245 anti-
sense sensitized strains representing a subset of genes that are
essential for growth and uses a capillary electrophoresis-based
detection system. In this case, effective titration of antisense
expression by xylose inducer can range from a conditional
knockout phenotype to a more modest level of growth suppres-
sion (20%) that maximizes target-based sensitivity for the
fitness test experiment. The key to success of this approach is
the pooling of strains into bins based on their xylose sensitivities
allowing for a competitive growth experiment to be performed
while maintaining appropriate target-depleted sensitization for
the essential gene targets represented in the array.
Through profiling of a diverse set of antibiotics (n = 59) with this
novel platform we have generated a reference set of AISS
profiles that allows us to recognize signatures reflecting antibac-
terial mechanisms at established drug targets. These targets
include metabolic enzymes as well as multienzyme complexes
involved in ribosomal translation, cell wall biosynthesis, and
DNA replication. Compound MOA can either be inferred directly
from AISS profiles or from pattern matching in 2D clustering to
the AISS profiles of compounds with defined MOAs. The clus-
tering of antibiotic U62162 with elongation inhibitor GE2270A
suggests a common mechanism (Figure 5). Much as the
‘‘compendium’’ approach has proved a powerful tool for eluci-
dating compound MOAs from gene expression profiles and
chemical genetic profiles from a yeast haploid deletion set
(Hughes et al., 2000; Parsons et al., 2006), such a reference
data set-based approach allows us to infer a biological MOA
for U-62162. Although this hypothesis requires further investiga-
tion, metabolic labeling experiments (not presented) show that
the compound is indeed a selective inhibitor of translation but
not of nucleic acid, cell wall, or fatty acid biosynthesis.
The AISS profile data set presented here provides insights into
the whole-cell MOAs of a wide range of antibiotics along with
information about gene function, some of which are highlighted
in this report. Prominent in the AISS cluster analysis of inhibitors
of translation and cell wall/membrane (Figure 5) are a limited
number of antisense strains that deplete across specific sub-
groups. For the ribosomal antibiotics, all but the classic amino-
glycosides and a pair of elongation inhibitors (GE2270A and
puromycin) show depletions in the rpsO-AS (ribosomal protein
S15) strain. For cell wall inhibitors, depletions in the pbp2-AS
strain appear to define a group of putative TP and TG inhibitors
that cluster distinctly from the major group of b-lactams,
including bona fide inhibitors of PBP2 TP or TG. While these
strains can serve as beacons of specific biological responses
in an AISS profile, they can also be adapted for use as individual
whole cell screens for the detection of target- and pathway-
specific antibiotics.
Notwithstanding the clear advantages AISS profiling provides
in determining theMOA of antibiotics, it does possess some limi-
tations. For example, the platform has been purposely biased to
represent genes essential for growth under laboratory condi-
tions; nonessential cellular processes that contribute to patho-
genesis including virulence factors and antibiotic resistanceChemistry & Biology 16, 8determinants have so far been excluded from study. Ionophores
with antibacterial activity, such as monensin and nigericin, and
the protonophore tetrachlorosalicylanilide fail to generate mech-
anistically informative AISS profiles (not presented). This may
reflect limitations of genome coverage in the current strain set
or the inability to detect such MOAs through the fitness test
approach. The discriminating power of the array is likely to be
enhanced by the inclusion of antisense strains or loss-of-func-
tion mutants corresponding to nonessential genes encoding
transcriptional regulators, efflux pumps, or virulence factors
that can influence susceptibility to particular antibiotics.
Biological constraints are also imposed on fitness test
screening within a bacterial pathogen. Unlike in eukaryotes,
gene operons and polycistronic transcripts can complicate
genetic depletion of individual targets by antisense interference
or other genetic means. Consequently, linking a compound to
its cognate target may not be as straightforward in instances
where antisense-induced strain depletions result from individual
antisense fragments targeting either a polycistronic message
(the most dramatic being the 29 member superoperon effected
by actinomycin and echinomycin) or two adjacent open reading
frames, as in the case of SAV1891-SAV1892-AS and SAV1754-
SAV1753-AS strains. Interestingly, although ddlA and murF are
cotranscribed, gene-specific antisense interference of these
targets produces specific strain hypersensitivities: D-cyclo-
serine specifically affects ddlA-AS and murF-AS strain deple-
tions, whereas other cell wall inhibitors broadly affect murF-AS
but not the ddlA-AS strain. Complex AISS profiles may also
result for compounds with MOAs associated with a single drug
target. For example b-lactam antibiotics specifically inhibit
bacterial growth by acylating essential PBPs. However, AISS
profiles capture not only their drug target (e.g., PBPA, PBP2,
and/or PBP3, depending on the b-lactam) but also multiple addi-
tional steps in peptidoglycan biosynthesis, which if impaired
sensitize S. aureus to these agents. Thus, the biological rele-
vance of such profiles not only underscores the general process
affected by b-lactams, namely cell wall assembly, but also
provides important clues as to subtle differences in biological
MOA and potential interactions between the drug target and
other cellular components.
Importantly, AISS profiling serves as a valuable MOA hypoth-
esis tool for characterizing new bioactive compounds. However,
additional genetic and/or biochemical evidence is required to
test such hypotheses. Indeed, in the accompanying paper by
Roemer and colleagues in this issue of Chemistry & Biology,
we demonstrate how AISS profiling of new synthetic antibacte-
rial compounds is used to guide genetic, biochemical, and cell
biological-based secondary assays and establish their likely
drug target, SAV1754, a previously uncharacterized cell surface
transmembrane protein involved in cell wall assembly (Huber
et al., 2009). Thus, the timely extension of fitness test profiling
tools for MOA determination in the bacterial pathogen S. aureus
should provide an important chemical genetic strategy to benefit
many aspects of antibacterial drug discovery.
SIGNIFICANCE
The search for new lead molecules in antibacterial drug
discovery is a daunting task that is complicated by the fact26–836, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 833
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natural product libraries have some level of intrinsic antibac-
terial activity. Establishing which of these molecules might
be working through an attractive target-based mechanism
and prioritizing them for lead optimization chemistry efforts
represents a significant bottleneck in the discovery process.
Based on an array of 245 target-depleted antisense strains
corresponding to essential genes, the S. aureus antisense
platform described in this paper offers a solution by yielding
reproducible information-rich profiles that reflect a com-
pound’s biological mechanism. As demonstrated with a
diverse set of reference antibiotics, inhibition of single
enzyme targets or multienzyme complexes can be reliably
and rapidly detected. The inclusion in the array of antisense
strains corresponding to uncharacterized S. aureus essen-
tial genes facilitates the identification of compounds inhibit-
ing growth through novel mechanisms (e.g., compound D;
Mott et al., 2008). In practice, this platform has utility as
a cell-based target selectivity assay to guide antibiotic
medicinal chemistry and natural product isolation chemistry
efforts. In addition, the underlying concepts of strain
binning, strain detection, and data analysis have potentially
broader application to other pathogens or model systems
where stable RNA interference technologies have been
established.
EXPERIMENTAL PROCEDURES
Plasmids and Strains
S. aureus strain RN4220 was used as host for all antisense plasmids (Novick,
1991). For new antisense vector construction, inverted gene fragments (200–
300 bp) spanning the target gene were subcloned into pEPSA5 vector BamHI
and SmaI sites (Forsyth et al., 2002) using standard techniques. Representa-
tive clones harboring gene fragments conferring the strongest conditional
growth phenotype in S. aureuswere selected for the array. Antisense plasmids
were introduced into RN4220 by electroporation (Kraemer and Iandolo, 1990)
and stable transformants were selected on LB chloramphenicol agar plates
(34 mg/ml). Gene annotation of the antisense strain set is based on the
S. aureus Mu50 genome (Kuroda et al., 2001), which is predicted to encode
864 monocistronic transcripts and 533 polycistronic operons (Wang et al.,
2004). The antisense strains described in this work (Table S1) are available
for noncommercial use following the standard Merck Material Transfer Agree-
ment and clearance procedures.
Xylose Titrations and Binning of Strains
Growth media used for all experiments was prepared from Miller’s Luria broth
base (single lot; Invitrogen), filter sterilized (0.22 mMmembrane; Millipore), and
supplemented with 34 mg/ml chloramphenicol for maintenance of antisense
plasmids (Sigma). Individual S. aureus antisense strains were grown indepen-
dently over three cycles (see Supplemental Experimental Procedures) in the
presence of xylose ranging from 0 to 100 mM generating dose response
curves with varying IC50 values, slopes, and minima. Strains were ordered
by IC20 values calculated using the values from the end of the third cycle
and were grouped into bins by ensuring an overlap of the IC10 and IC30 of
neighboring strains and targeting an optimum of ten strains per bin
(Table S1). Some manual adjustments were made to bin composition based
on empiric observations and previous strain performance in early prototype
versions of the profiling platform. Xylose concentrations for each individual
bin were determined by averaging the IC10 values for all strains represented
in the bin. This resulted in 24 unique bins having 6–12 strains per bin with
xylose concentrations for the entire array ranging from 1.8-55 mM. In this
bin configuration two antisense strains, AS-169 (SAV1901-SAV1900) and
AS-302 (SAV1113-ylaO), were eliminated from all experiments because of
poor peak area signal in the DMSO mock treatment controls.834 Chemistry & Biology 16, 826–836, August 28, 2009 ª2009 ElsevPlatform Instrumentation
The fully automated assay system for processing 384 well growth plates
through three cycles of growth consisted of a Tecan Genesis (or Evo) with
a ROMA for plate handling, a Hereaus Cytomat 6000 for plate incubation,
a Biotek PowerWaveHT for cell growth end point determination, and a Matrix
PlateMate 2 3 2 for back dilutions. One experimental unit for this platform is
defined as six initial 384 well growth plates containing a total of 12 different
compounds each dosed at six different concentrations and 12 DMSO mock
treatment controls. Instruments and scheduling were controlled through
Tecan’s FACTS software with custom integration code for nonstandard instru-
ments. Matrix PlateMatePlus instruments were used to process microplates
for microbiology and molecular biology steps (details in Supplemental Exper-
imental Procedures). An ABI9700 Dual 384 well thermocycler was used for
multiplex PCR and products were analyzed on an ABI3730 genetic analyzer.
Oligonucleotide Markers and Multiplex PCR Primer Sets
Strain-specific oligonucleotides (IDT) and the antisense plasmid inserts to
which they selectively anneal are described in Table S7. The makers include
a synthetic 50 7 bp extension (GTTTCTT) to improve multiplex PCR efficiency.
The primers (Tm 48–52
C, minus extension) were designed to generate frag-
ments in the 200 to 500 nt range when used in combination with an anchored
VIC-labeled vector primer (common to all plasmids) that anneals to the prox-
imal xylose promoter (50VIC-CAGCAGTCTGAGTTATAAAATAG, synthesized
by ABI). Performance of individual primers was initially optimized in PCR reac-
tions with mock cell lysates (all strains as template) to eliminate those yielding
secondary products (in singleplex PCR) or poor signal (in multiplex PCR). Vali-
dated primers were organized into eight multiplex sets of 30–32 that yield well-
spaced (R4 nt gap) strain-specific PCR fragments readily resolvable by
ABI3730 capillary electrophoresis with ABI Genemapper software.
Data Normalization, Statistical, and Cluster Analysis
Individual variability of an oligonucleotide marker was normalized by calcu-
lating the marker’s area as a percentage of total composite signal for its partic-
ular multiplex marker set (%pi =pi=
P
pn). Subsequently, the strain depletion
ratio was calculated as a log10 of the median DMSO control percent area
(calculated from the entire set of data from one experimental unit; see Platform
Instrumentation section) divided by the individual strain percent area
(Ri = log10ðmedianð%CÞ=%piÞ). This approach required defining a minimum
background value for potential fully depleted strains. Statistical significance
was determined as a p-value utilizing an error model generated for each
individual strain across a discrete set of known standards and unknown test
samples selected to represent total coverage of all strains within the array
set. Z score or Xdev was calculated as log10 depletion ratio minus the median
log10 depletion ratio for the error model divided by the median absolute
deviation (Xdev = ðRi medianðRcÞÞ=medianðjRi medianðRcÞjÞ). P-value
was then calculated as the standard complementary error function
(p value= erfcðjXdev= ﬃﬃﬃ2p jÞ. Calculated log10 depletions and corresponding
p-values were then loaded into Rosetta Resolver as Ratio Experiments for
subsequent cluster analysis. Reference compound profiles were then repre-
sented in Resolver as combos in which several (4–10) appropriately dosed
representative experiments were combined into one and the log10 ratio calcu-
lated as an error-weighted mean of the log10 ratio from each experiment. The
combined log10 ratio error was calculated as a blend of two error components,
the ‘‘propagated’’ error and the ‘‘scattered’’ error. The propagated error is the
average of the log10 ratio divided by square root of the number of experiments
(p=1=n
Pn
i =1 Ri=
ﬃﬃﬃ
n
p
) and the scattered error (s) is an error-weighted standard
deviation of the profile log10 ratio values. The blend of the two components is
a linear blending where log10 ratio error=p=n+ ðsðn 1Þ=1Þ. Thus the com-
bined log10 ratio error equals the propagated error if n = 1 but the dominant
contributor is the scattered error as n increases. Two-dimensional cluster anal-
ysis was performed on the combined experiments (combos) in Rosetta
Resolver utilizing an agglomerative algorithmwith average link heuristic criteria
and a cosine correlation similarity measure. The antisense strains used for the
clustering exercise were selected if they were significantly depleted in the
profiles for those compound treatmentsmaking up a given combo experiment.
The thresholds set for determining strain significance for each set of
compound profiles were at least a 5-fold depletion and p-value %0.01 in at
least 75% of the experiments making up the combo for the given compound.ier Ltd All rights reserved
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in this way they were then added to a Resolver sequence set that was used to
build the 2D cluster shown in Figure 5.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, two
figures, and seven tables and can be found with this article online at http://
www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00214-2.
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